ICMR National Institute of Medical Statistics, Ansari Nagar, New Delhi 110029, India.
ICMR National Institute of Pathology, Safdarjung Hospital Campus, Ansari Nagar, New Delhi 110029, India.
Int Immunopharmacol. 2024 Dec 5;142(Pt A):112949. doi: 10.1016/j.intimp.2024.112949. Epub 2024 Sep 5.
MDSCs (myeloid-derived suppressor cells) are crucial for immune system evasion in cancer. They accumulate in peripheral blood and tumor microenvironment, suppressing immune cells like T-cells, natural killer cells and dendritic cells. They promote tumor angiogenesis and metastasis by secreting cytokines and growth factors and contribute to a tumor-promoting environment. The accumulation of MDSCs in cancer patients has been linked to poor prognosis and resistance to various cancer therapies. Targeting MDSCs and their immunosuppressive mechanisms may improve treatment outcomes and enhance immune surveillance by developing drugs that inhibit MDSC function, by preventing their accumulation and by disrupting the tumor-promoting environment. This review presents a detailed overview of the MDSC research in cancer with regulation of their development and function. The relevance of MDSC as a prognostic and predictive biomarker in different types of cancers, along with recent advancements on the therapeutic approaches to target MDSCs are discussed in detail.
髓源性抑制细胞（myeloid-derived suppressor cells，MDSCs）在癌症的免疫系统逃逸中起着关键作用。它们在外周血液和肿瘤微环境中积累，抑制 T 细胞、自然杀伤细胞和树突状细胞等免疫细胞。它们通过分泌细胞因子和生长因子促进肿瘤血管生成和转移，并有助于肿瘤促进环境的形成。癌症患者中 MDSC 的积累与预后不良和对各种癌症治疗的耐药性有关。通过开发抑制 MDSC 功能、防止其积累和破坏肿瘤促进环境的药物来靶向 MDSC 及其免疫抑制机制，可能改善治疗效果并增强免疫监测。本文详细综述了 MDSC 在癌症中的研究，包括其发育和功能的调控。还详细讨论了 MDSC 作为不同类型癌症的预后和预测生物标志物的相关性，以及针对 MDSC 的治疗方法的最新进展。
